Forte Biosciences Just Plummeted 80%: Here's Why

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday.

What Happened: The clinical trial of Forte Biosciences FBRX lead drug FB-401 failed to meet a statistical significance, the company said.

Topline data from a Phase 2 trial for the treatment of atopic dermatitis did not reach its primary endpoint. The company said positive endpoints were observed in key secondary endpoints.

“The topline data is disappointing and we will continue to analyze the data, however, given the readout we will not continue to advance FB-401,” Forte CEO Paul Wagner said.

Check out Benzinga's full FDA calendar

The company had cash balances of $50.8 million as of June 30.

“We expect to provide investors with an update on the future plans of the company over the next several months," Wagner said.

The company said it will not host its previously scheduled conference call on Sept. 7.

FBRX Price Action: Forte Biosciences shares are down 82% to $5.16 at the time of publication in after-hours trading. Shares have traded between $23.61 and $53.99 over the last 52 weeks.

Posted In: dermatitisDermatologyBiotechNewsHealth CareAfter-Hours CenterMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.